Ember LifeSciences and Alfresa form strategic alliance to strengthen pharmaceutical cold chain in Japan. Thursday, July 30, 2026 Ember LifeSciences has entered into a capital and business alliance with Alfresa Corporation to enhance pharmaceutical cold chain logistics in Japan. As part of the agreement, Alfresa will invest in Ember through its Series A preferred stock and gain exclusive sales rights for Ember's healthcare cold chain solutions in the Japanese market. The partnership will focus on improving the quality of temperature-controlled pharmaceutical distribution, including the evaluation of the Ember Cube and related technologies for Alfresa's Home Care Delivery service. The service supplies specialty medicines directly from healthcare providers to patients' homes. Ember's Series A funding round also includes investments from Amgen, Cardinal Health, Carrier and Sea Court Capital. The new investment is expected to support Ember's business expansion while strengthening collaboration between the two companies. Ember develops pharmaceutical cold chain technologies that combine temperature-controlled transport with real-time shipment monitoring. Its Ember Cube 2 maintains temperatures between 2°C and 8°C for more than 72 hours while continuously tracking shipment conditions and location. The reusable container is also designed to reduce packaging waste compared with conventional single-use shipping solutions. Alfresa is Japan's largest pharmaceutical wholesaler by domestic net sales. The alliance supports its efforts to strengthen cold chain capabilities as demand for temperature-sensitive biopharmaceuticals and vaccines continues to increase.

Ember LifeSciences has entered into a capital and business alliance with Alfresa Corporation, a subsidiary of Alfresa Holdings Corporation and Japan's leading pharmaceutical wholesaler. The partnership aims to improve pharmaceutical cold chain logistics across Japan. As part of the alliance, Alfresa will invest in Ember's Series A preferred stock and obtain exclusive sales rights in Japan's healthcare sector for Ember's solutions. Other Series A investors include Amgen, Cardinal Health, Carrier and Sea Court Capital. Alfresa will evaluate the Ember Cube 2 and related technologies for its Home Care Delivery service, which delivers specialty pharmaceuticals directly to patients' homes. The Ember Cube 2 maintains temperatures between 2°C and 8°C for over 72 hours whilst monitoring shipment conditions and location in real time. The partnership addresses growing demand for precise cold chain logistics as temperature-sensitive biopharmaceuticals and vaccines increase.

Ember LifeSciences has raised $27 million in Series A funding, according to filings with the US Securities and Exchange Commission. Amgen Ventures participated in the round. The company launched as an offshoot of Ember Technologies, maker of the temperature control mug that has surpassed $500 million in total sales. Ember LifeSciences applies the parent company's proprietary temperature control technology to medicine distribution, aiming to improve transportation of life-saving medicines and vaccines globally. The company filed the notice under Regulation D of the Securities Act of 1933, which allows securities sales without registration. Clay Alexander serves as chief executive officer.